Alessandro Morabito

Oncology — Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Italy

LeadR Profile

1 912 ScienceLeadR Reputation 1912
Network Map

Oncology

Subspecialties: Pulmonology - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026

Source: PubMed

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 397

Citations

Citations: 33 911 1st author: 32 Last author: 52 Unique author: 6


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.
cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma
J Clin Oncol Top journal20262
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells.
cells, lung, gefitinib, micrornas, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, cell line, small cell lung carcinoma, therapeutics, mutation
Cells20260
Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study.
cells, lung, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma
Eur J Cancer20260
Imaging and AI in tertiary prevention of lung cancer: Narrative review and clinical perspectives.
lung, neoplasms, lung neoplasms, deep learning, therapeutics, learning, artificial intelligence, tertiary prevention
Multidiscip Respir Med20260
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD.
lung, safety, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, drug tapering, therapeutics
Ann Oncol Top journal20260

Clinical Studies 54

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 3 32
Phase 2 11
Phase 2/Phase 3 7
N/A 3
Phase 1 1

By status:

Completed 22
Active not recruiting 12
Recruiting 11
Unknown 6
Terminated 2
Not yet recruiting 1

By type:

Interventional 51
Observational 3

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 2
multicentric5to9 1
multicentricup10 47

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib
Phase 3Active not recruiting2021
Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment
2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation
Phase 3Not yet recruiting2026
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated KRAS G12C Mutated Advanced or Metastatic Non Squamous Non Small Cell Lung Cancer
2024-518365-10-00 — cells, pemetrexed, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, carboplatin
Phase 3Recruiting2025
A Study of Dato DXd in Combination With Durvalumab and Carboplatin for First line Treatment of Advanced NSCLC Without Actionable Genomic Alterations
2023-505993-14-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, carboplatin, chemotherapy
Phase 3Active not recruiting2023
BEAMION Lung 2 A study to test whether zongertinib (BI 1810631) helps people with advanced non small cell lung cancer with HER2 mutations compared with standard treatment
2023-504308-27-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation
Phase 3Active not recruiting2024

LeadR Networks

Main global connection map